Compare HYPR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | LUNG |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.4M | 97.1M |
| IPO Year | 2021 | 2020 |
| Metric | HYPR | LUNG |
|---|---|---|
| Price | $0.67 | $2.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.03 | ★ $3.70 |
| AVG Volume (30 Days) | 893.1K | ★ 993.2K |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $13,563,000.00 | ★ $90,497,000.00 |
| Revenue This Year | $49.18 | $0.33 |
| Revenue Next Year | $29.74 | $8.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.22 | ★ 8.01 |
| 52 Week Low | $0.70 | $1.13 |
| 52 Week High | $1.94 | $3.25 |
| Indicator | HYPR | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 64.05 |
| Support Level | $0.70 | $1.26 |
| Resistance Level | $1.05 | N/A |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 16.71 | 64.45 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.